-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2019 European Crohn's Colitis Organization recommends using using us as a first-line biological agent for the treatment of moderate to severe Crohn's disease.
with the new mechanism of white methicillin, Usnu monoantigen has the characteristics of rapid effectiveness and continuous maintenance of remission.
the approval of usmano monotherapy marks an important progress in the treatment of Crohn's disease in China, and also provides a brand-new treatment for crohn's disease patients in China, especially those with moderate to severe diseases.
But the relationship between peak concentrations of the drug during the first two weeks of use and disease prognosis is not yet known, and the study aims to assess the relationship between the serum concentration of usthabyn resistance during the two-week treatment and endoscopic and bio-chemical remission in patients with CD.
In this forward-looking observational study, due to endoscopic markers of active CDs, the researchers measured the concentration of Usnu monoantigen in serums in 41 consecutive patients with using Usnu monoantigen (using dose of Usnu monoantigen: 6 mg / kg, intravenously, and then 90 mg every 8 weeks).
researchers measured the exposure of usanut monoantigen (peak concentration immediately after intravenous infusion, concentration in week 2, and curve area from week 2 to week 2).
we investigated the correlation between these parameters and endoscopic mitigation.
results showed that 10 patients (24.4%) achieved endoscopic remission in week 24, 17 patients (41.5%) reached biological index remission in week 8, 17 patients (41.5%) reached biological remission in week 16, and 21 patients (51.2%) reached biological remission in week 24.
the peak concentration associated with endoscopic mitigation was AAUC: 0.717; (95% CI, 0.517-0.916);
, the researchers in this study determined that serum concentrations as early as 1 hour after intravenous infusion can be used to predict CD patients who are most likely to achieve endoscopic remission (the higher the better).
this early measurement can be used to optimize the treatment of CD.
。
